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Aims: It has been shown previously (by immunohistochemistry) that gastric adenocarcinomas harbour-
ing Epstein-Barr virus (EBV) frequently lose p16 protein. This study aimed to examine the mechanisms
of inactivation of the CDKN2A gene and correlate the results with clinicopathological features.
Methods: Methylation specific polymerase chain reaction was used to detect CDKN2A promoter
methylation in gastric adenocarcinomas from American patients. In addition, immunohistochemistry
was used to detect the loss of the p16 protein and in situ hybridisation was used to detect the presence
of EBV. The tumours were also analysed for the presence of microsatellite instability.
Results: Eleven (10%) of 107 tumours harboured EBV in the malignant cells. In gastric cancers without
EBV, 32% exhibited CDKN2A promoter methylation and 26% had p16 protein loss. In contrast, 91%
of the tumours containing EBV had CDKN2A promoter methylation (p = 0.0003) and 90% showed
p16 protein loss (p = 0.0001). The presence of EBV was also associated with male sex (p = 0.03) and
was more common in tumours from Texas Hispanics than from non-Hispanic whites or
African–Americans (p = 0.01). EBV was not associated with microsatellite instability, histological sub-
type, stage, or grade of the tumour, or age or survival time of the patient.
Conclusions: The presence of EBV in gastric adenocarcinomas is strongly associated with CDKN2A
inactivation by promoter methylation. In addition, these findings suggest that there are ethnic
differences in tumour virology and pathogenesis.
Gastric cancer is distinctive in its association with twodifferent infectious agents that may contribute to thedevelopment of the disease. The first of these associa-
tions to be identified was that with Helicobacter pylori, a bacte-
rium that colonises the stomach and serves as a risk factor for
gastric carcinoma of the intestinal subtype.1–3 The second
infectious agent found to be associated with a subset of gastric
cancers is the Epstein-Barr virus (EBV). This virus was
initially recognised for its association with Burkitt’s
lymphoma, Hodgkin’s disease, and nasopharyngeal carci-
noma. More recently, it was found to be present in gastric
adenocarcinomas, especially lymphoepithelioma-like (LEL)
variants, which morphologically resemble nasopharyngeal
carcinomas, but also in gastric cancers not morphologically
distinguishable from non-EBV containing gastric
adenocarcinomas.4–10 The virus is present in 3–16% of gastric
adenocarcinomas, in 67–100% of LEL carcinomas, and in
29–35% of gastric remnant adenocarcinomas7 11–17 (for a
review, see Takada18). Monoclonality in the size of the fused
termini of the viral genome indicates that the virus was
present in the original cell from which the tumour arose, and
identification of EBV in premalignant lesions further impli-
cates the virus as an early acting contributor to the process of
carcinogenesis.11 12 19–22 When gastric epithelial cells were
infected with EBV containing a selectable marker, clones arose
that had higher proliferation rates and a higher saturation
density than control cells, and which formed colonies in soft
agar.23 Clearly, EBV is able to drive gastric epithelial cells in
vitro towards a malignant phenotype, but the mechanisms by
which the virus accomplishes this remain obscure.
The CDKN2A gene encodes p16, or cyclin dependent kinase
inhibitor 2a, also known as INK4a, for inhibitor of cyclin
dependent kinase 4a. Binding of p16 inhibits kinase activity of
cyclin dependent kinase 4 or 6, so that the retinoblastoma
protein is hypophosphorylated and consequently binds E2F
transcription factors, thus inhibiting cell cycle progression
from G1 to S.24 25 The CDKN2A gene is inactivated in a wide
variety of human cancers, by mutation, by homozygous muta-
tion, or by promoter methylation,26–32 as reviewed in Liggett
and Sidransky32 and Ruas and Peters.33 Homozygous deletions
of CDKN2A are reported to occur in approximately 10% of
gastric cancers.34 Chen et al reported the presence of aberrant
CDKN2A transcripts, including intragenic deletions in five of
11 diffuse-type gastric cancers and in three of 10 intestinal-
type gastric cancers.35 Others have found p16 mutations to
occur in 10% or less of gastric cancers.34 36–38 CDKN2A promoter
methylation has been found in 42% of gastric cancers.39
“Epstein-Barr virus is able to drive gastric epithelial cells
in vitro towards a malignant phenotype, but the mecha-
nisms by which the virus accomplishes this remain
obscure”
In a previous report,40 we found that EBV associated gastric
adenocarcinomas showed p16 loss, as measured by immuno-
histochemistry (IHC), more frequently than did non-EBV
associated tumours. To gain insight into the mechanisms of
this loss, we performed methylation specific polymerase chain
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reaction (MS-PCR) and microsatellite analysis on a larger set
of gastric cancers. Here, we report the striking association of




Formalin fixed, paraffin wax embedded gastrectomy speci-
mens (n = 122) from patients with gastric adenocarcinoma
were obtained from hospitals in San Antonio, Texas (n = 67);
New Orleans, Louisiana (n = 50); and Rochester, Minnesota
(n = 5). Specimens were serially acquired, but cases with
small amounts of tumour in the section were omitted from the
study, as were cases with finely dispersed tumour cells. Meth-
ylation analysis data were obtained for 118 of the 122 cases,
and EBV analysis data were obtained for 107 cases. The
ethnicity, age, and sex of the patient and anatomical site of the
tumour were obtained from medical records or tumour regis-
tries. The ethnic groups represented were white (persons of
European ancestry; n = 48, 36 men, 12 women), Texas
Hispanics (persons of predominantly Mexican ancestry;
n = 47, 35 men, 12 women), and African–Americans (n = 25,
16 men, nine women); the ethnic origins of two patients were
unknown. Staging was performed using standard TNM
criteria.41 Tumours were graded and classified as intestinal,
diffuse, or mixed subtype by an experienced surgical patholo-
gist (JCB) according to the criteria of Laurén.42 Survival data
were available for 100 patients from Texas and Louisiana. All
specimens and patient information were obtained with the
approval of the institutional review boards of the Louisiana
State University Health Sciences Center and/or the University
of Texas Health Sciences Center at San Antonio. This set of
cases overlaps but is not identical to that used in our previous
study of EBV in gastric cancer.22
Harvesting of DNA from formalin fixed, paraffin wax
embedded gastric tumour samples
Paraffin wax embedded sections of gastric adenocarcinomas
were prepared for microdissection as described previously.43
Tumour cells and benign cells were harvested by laser capture
microdissection (LCM) with the PixCell I instrument (Arctu-
rus Engineering, Mountain View, California, USA) using a
30 µm laser spot with 50 to 60 mW power and a 50 to 100 msec
pulse width. Cell preparations of 2000 to 3000 pulses were
harvested and digested in 40 µl of proteinase K (1 mg/ml in
50mM Tris/HCl buffer, pH 8.0, with 1mM EDTA and 0.45%
Tween 20) at 52°C overnight. Digested material was heated at
95°C for 15 minutes to denature the proteinase K and was
used as template for PCR without additional purification.
Microsatellite instability
Gastric tumours in our study had been categorised previously
for microsatellite instability (MSI)43 following recommenda-
tions of the National Cancer Institute (NCI) Workshop on
Microsatellite Instability. 44 In accordance with these guide-
lines, cases were designated as having high frequency micros-
atellite instability (MSI-H), low frequency microsatellite
instability (MSI-L), or as being microsatellite stable (MSS),
using the five markers recommended by the NCI convention,
BAT25, BAT26, D2S123, D5S346, and D17S250. We used the
NCI convention nomenclature of MSI-H if amplification of
DNA from the tumour produced bands with altered mobility
at 30% or more of the markers, MSI-L if amplifications showed
alterations in less than 30% of markers, and MSS if there were
no alterations.
Bisulfite modification
Digested samples from LCM harvested cells (20 µl) were
denatured with 2 µl of 3M NaOH at 75°C for 15 minutes.
Bisulfite modification was initiated by adding 250 µl of freshly
prepared, pH 5.0, 4.8M sodium bisulfite and 14 µl of 10mM
hydroquinone and incubating for four hours at 55°C. The
samples were concentrated with centrifugal filter devices
(Centricon YM-30, Millipore Corporation, Bedford, Massachu-
setts, USA). Desulfonation was performed by adding 4.5 µl of
3M NaOH to each sample, incubating at 37°C for 15 minutes,
and then adding 28 µl of 5M ammonium acetate to neutralise
the solution. DNA was precipitated with ethanol using glyco-
gen as a co-precipitant and resuspended in 25 µl of water.
Methylation specific polymerase chain reaction
The sodium bisulfite modification technique relies on the
capacity of bisulfite to convert unmethylated cytosine
residues, but not 5-methylcytosine, to uracil by
deamination.45 Primer sequences, as described by Herman et
al, discriminated methylated from unmethylated sequences of
the CDKN2A promoter46 based upon the chemically induced
differences induced by bisulfite modification. Forward primers
were labelled with γ-32P ATP using T4 polynucleotide kinase.
PCR mixtures contained 100nM of each primer, 200µM of
each dinucleotide triphosphate, and 1.5mM MgCl2. Annealing
temperatures for primers were 60°C for the primers specific for
unmethylated DNA and 63°C for the primers specific for
methylated DNA. After 95°C for three minutes, amplifications
were carried out for 40 cycles consisting of 95°C for 45
seconds, 60°C/63°C for 45 seconds, and 72°C for one minute.
PCR products were electrophoresed on 6% polyacrylamide gels
for two hours at 45 W. Gels were dried under vacuum at 80°C
and analysed by autoradiography on Kodak X-Omat AR film.
Immunohistochemistry
Unstained sections (5 µm) were cut on to capillary gap slides,
and heated at 60°C for 20 minutes. The anti-p16 monoclonal
antibodies used were: Ab7 (Lab Vision Corporation, Fremont,
California, USA) and clone PMG175-405 (PharMingen, San
Diego, California, USA). Normal mouse IgG was used as a
negative control. Sections of all cases were incubated with Ab7
at 1 µg/ml at 4°C overnight, after antigen retrieval in 0.1M
EDTA, pH 8.0 (20 minutes at 95–100°C).47 A subset of cases
was also reacted with the PMG175-405 monoclonal antibody,
as described previously.48 The Vectastain Elite ABC kit from
Vector (Burlingame, California, USA) was used for detecting
bound antibodies, according to the manufacturer’s recom-
mendations. Diaminobenzidine with a haematoxylin counter-
stain was used for colour development. Normal colonic
mucosa and a p16 positive lung cancer xenograft were used as
external positive controls. In addition, non-neoplastic stromal
cells served as internal positive controls for p16 in every
tumour section. A mesothelioma and pancreatic adenocarci-
noma, both of which were p16 negative, were used as external
negative controls. Sections were examined for evidence of
nuclear staining above any cytoplasmic background; cytoplas-
mic staining itself was disregarded.48 If there was nuclear
staining in a diffuse or mosaic distribution throughout the
tumour, it was considered positive for p16. If the neoplastic
nuclei failed to stain whereas admixed non-neoplastic cells
reacted positively, the lesion was scored as negative. In a sub-
set of carcinomas, loss of p16 reactivity was not diffuse, but
limited to well defined areas within the lesion. This staining
pattern was also considered abnormal and may reflect a rela-
tively late event in the development of the tumour.
In situ hybridisation
In situ hybridisation for EBV encoded RNA 1 (EBER1) and U6
was performed on paraffin wax embedded sections, as
described previously, using digoxigenin labelled riboprobes
complementary to EBER1 transcripts.22 U6 transcripts served
as a control for RNA preservation because U6 is a ubiquitous
cellular RNA similar in size, copy number, and nuclear locali-
sation to EBER1. Dr R Ambinder provided probe templates for
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EBER1 (RA386) and U6 (RA390). Positive controls included
EBV related Hodgkin’s disease cases, and negative controls
included normal epithelium and other non-malignant struc-
tures in each case. Rare small lymphocytes stained with the
EBER1 probe in some tumour sections, but only tumour spe-
cific EBER1 staining was considered to be a positive result.
Statistical analysis
The relation between EBV or methylation status and categori-
cal variables such as sex, site, and grade was analysed using
the χ2 test or Fisher’s exact test. The time to event was used to
calculate the relative hazard of death given EBV status. A
Kaplan-Meier curve was constructed, and the association with
EBV status was determined using the log rank test. All analy-
ses were done with SAS (SAS Institute Inc, Cary, North Caro-
lina, USA).
RESULTS
To determine the mechanism of p16 inactivation in gastric
cancers, we performed MS-PCR for the promoter region of the
CDKN2A gene and obtained results from 118 gastric
adenocarcinomas. Of these, 44 (37%) showed methylation of
the CDKN2A promoter (fig 1). Details of clinicopathological
associations with methylation are described elsewhere (QN Vo
et al, unpublished data, 2002).
For 107 of the 118 cases, EBV analysis by in situ hybridisa-
tion was also performed, and 11 (10%) cases were found to be
positive. Table 1 shows the clinicopathological findings
regarding the 11 EBV positive cases. None of the 11 cases was
a gastric remnant tumour. All but one of the 11 EBV positive
cases were also positive for methylation, showing a highly sig-
nificant association (p = 0.0003). Two tumours had LEL mor-
phology, and two more had focal LEL patterns. Table 2 shows
the detailed associations of EBV infection and other clinical
features of the tumours.
This series of patients was larger and, coincidentally, more
broadly representative of the major south Texas and Louisiana
ethnic groups than the group that we examined previously for
EBV22; 50 cases overlapped both studies. EBV was associated
with male sex (p = 0.03) and Hispanic ethnic origin (p = 0.01).
Hispanic men made up only 29% of the patients in our study,
but were 82% of the patients with EBV associated tumours. EBV
was associated with nine of 43 tumours from Hispanic patients,
compared with two of 44 from white patients; none of the 21
African–Americans had EBV present in their tumours. In
Hispanic men, 28% of gastric cancers were EBV associated,
compared with 6% of tumours from white men.
The tumours were examined for p16 protein by IHC, and
data for 118 cases were obtained; 36 (31%) of these showed
complete or focal loss of p16 protein. Both EBV status and p16
IHC data were available in 106 cases. Of the 10 EBV positive
cases for which p16 IHC data were obtained, nine were nega-
tive for p16 protein (p = 0.0001; fig 2).
No significant associations were shown between EBV status
and stage, histological subtype, or grade (table 2). Information
regarding the anatomical location of the tumour was available
for only three of the 11 EBV positive adenocarcinomas (two
arose in the body, one in the cardia). Median survival for
patients with EBV positive tumours was 207 days, compared
with 329 days for patients with EBV negative tumours, but
this difference was not significant; neither was there a signifi-
cant difference in the ages of the patients who had EBV posi-
tive and negative tumours.
We found no significant association with EBV status and MSI.
Nine of the 11 EBV positive cases were MSS, one was MSI-L
(showing MSI at one of the five NIH convention markers), and
one was not completely characterised using the NIH conference
markers, but appeared to be MSS, based on its stability at marker
BAT26 and at three dinucleotide repeat markers.
DISCUSSION
In this set of gastric adenocarcinomas, 10% were EBV related,
as defined by in situ hybridisation to EBER transcripts, a
method that is considered the gold standard for defining EBV
associated tumours. This result was similar to the percentage
reported by us (12%) in a previous study on a smaller set of
Figure 1 Lanes marked “U” contain PCR products amplified with
primers specific for unmethylated sequences, and lanes marked “M”
contain PCR products amplified with primers specific for methylated
sequences. Analysis of five gastric adenocarcinomas by methylation
specific PCR shows that tumours 1 and 5 have bands indicating the
presence of methylation in the CDKN2A promoter. Tumours 2, 3,
and 4 have bands indicating only the unmethylated form of the
promoter. Tumour 1 is an Epstein-Barr virus associated tumour.
Table 1 Clinicopathological findings in 11 EBV associated gastric cancers
Case Pattern MS-PCR p16 IHC Ethnicity Sex Age (years)
1 Intestinal + – Hispanic Male 80
2 Diffuse + – Hispanic Male 70
3 Intestinal + – Hispanic Male 61
4 Intestinal + – Hispanic Male 56
5 LEL – – Hispanic Male 67
6 Intestinal + – Hispanic Male 56
7* Mixed + + Hispanic Male 60
8* Intestinal + – Hispanic Male 63
9 Intestinal + ND Hispanic Male 82
10 LEL + – White Male 66
11 Intestinal + – White Male 70
*Had focal areas resembling LEL.
EBV, Epstein-Barr virus; IHC, immunohistochemistry; LEL, lymphoepithelioma-like morphology; MS-PCR,
methylation specific polymerase chain reaction; ND, not done.
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mostly North American cases,22 and similar to the percentage
reported in a study on Japanese Americans (10%).7 Similar
percentages have also been reported by other groups18 in
patients from areas with a higher incidence of gastric cancer,
and somewhat higher values (16%) were reported in another
set of American gastric cancers.5
The current cohort of patients with gastric cancer is more
ethnically diverse than in our previous study. Our current study
included non-Hispanic white, Hispanic, and African–American
populations, mostly from South Texas and Louisiana. Remark-
ably, nine of the 11 patients with EBV positive tumours were
found to be Hispanic men. In south Texas, Hispanic men have an
increased incidence of gastric cancer, over twice as high as that
of non-Hispanic white men.49 It is possible that EBV contributes
to this increased risk in this population. However, a study of 135
consecutive gastric cancers in Mexico found only 8% of cases to
be EBV related, a proportion consistent with results reported in
North American and European patients.50 A population based
study of south Texan ethnic groups would be useful to confirm
and characterise the interesting variation in host–virus interac-
tions that our data suggest.
Geographical variations in EBV associated tumours have
long been noted. Burkitt’s lymphoma, the first tumour known
to be associated with EBV, is found primarily in equatorial
Africa51 and in New Guinea.52 Hodgkin’s disease is more
frequently associated with EBV in Hispanic Americans.53 EBV
associated nasopharyngeal carcinoma has its highest inci-
dence in Southeast Asia.54 The reasons for such geographical
or ethnic variations remain obscure because EBV infection is
carried by over 90% of adults worldwide.
“The ability of the virus to control the expression of viral
genes by promoter methylation provides a selective
advantage that allows the virus to persist in the host for
many years”
Previously, we found in gastric cancers a significant associ-
ation between EBV and p16 loss, as determined by IHC.40 This
association was confirmed in our current set of tumours
(p = 0.0001). Furthermore, the presence of EBV was highly
associated with methylation of the CDKN2A promoter
(p = 0.0003). In all cases but three, tumours were both nega-
tive by immunostaining and methylation positive. In one case,
IHC could not be performed, but the tumour showed
methylation. In another case, a tumour with methylation was
p16 positive by IHC. Such an event could occur if methylation
was present in only one allele of the gene. In the third case, no
methylation was present, although p16 protein was not
detected by IHC. Such results could be explained by gene
inactivation by mutation or homozygous deletion.
Table 2 Clinical and biological features in association with EBV
EBV positive EBV negative p Value
Sex (n=108)
Male 11 67 0.03
Female 0 30
Ethnicity (n=108)
White/non-Hispanic 2 44 0.01
Texas Hispanic 9 34
African–American 0 21
MS-PCR (n=107)
Unmethylated only 1 65 0.0003
Methylated 10 31
p16 IHC (n=106)
Positive 1 71 0.0001
Negative 9 25
Mean (SEM) age (n=108) 66.5years(2.6) 68.3years(1.4)
Under 70 7 48
70 or older 4 49 NS
Microsatellite instability (n=106)













0 10 88 NS
1 1 9
Stage (n=106)
0–II 5 53 NS
III–IV 6 42
Tumour grade (n=109)




Intestinal 8 80 NS
Diffuse 2 13
Mixed 1 5
Unless otherwise noted, values are number of patients.
EBV, Epstein-Barr virus; IHC, immunohistochemistry; MSI-L, low frequency microsatellite instability; MSI-H,
high frequency microsatellite instability; MSS, microsatellite stable; MS-PCR, methylation specific polymerase
chain reaction; NS, not significant.
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Suppression of p16 expression associated with EBV
infection or EBV proteins has been observed in other systems.
In mouse embryo fibroblasts, EBV latent membrane protein 1
(LMP1) acts to prevent senescence by inhibiting the induction
of p16.55 Consistent with the capacity of EBV to inactivate p16,
we and others have previously reported frequent p16 loss (as
determined by IHC) in nasopharyngeal carcinomas.56 57
As with infection with H pylori, EBV infection persists over
decades, evading attempts by the immune system to eradicate
it. Normal individuals live in symbiosis with the virus by
mounting an effective defence against EBV driven cell prolif-
eration through the response of CD8 positive T cells.58–60 The T
cells of individuals with EBV associated gastric cancer are able
to cause regression of proliferating foci of exogenously
infected autologous B cells.11 In the presence of a vigorous
immune response, the virus apparently evades immune
surveillance by maintaining latency, in which very few viral
genes are expressed, and this control is achieved largely by
promoter methylation.
EBV appears to be distinctive among large DNA viruses in
showing a lower CpG content than would be expected by
chance.61 This could be explained by its use of methylation in
suppressing the expression of viral proteins. Because of the
spontaneous deamination of methylated cytosines, CpGs tend
to be reduced in the viral genome.
In nasopharyngeal carcinomas, lymphomas, and normal B
cells, methylation in the viral CpG rich BamH1 C and W pro-
moters controls expression of the EBV encoded nuclear
antigen (EBNA) proteins.62–67 In vitro studies of Burkitt’s
lymphoma cell lines68 and nasopharyngeal carcinoma cells69
have shown that the expression of LMP1 is associated with
hypomethylation of the LMP1 regulatory sequences (for a
review, see Robertson70). It seems that the ability of the virus
to control the expression of viral genes by promoter methyla-
tion provides a selective advantage that allows the virus to
persist in the host for many years.
Extrapolations regarding patterns of methylation in other
EBV associated diseases must be performed with caution
because the mechanism by which EBV contributes to gastric
cancer may be distinct from the mechanisms occurring in
other EBV related systems. Under in vitro conditions, the
expression of LMP1 alone can transform fibroblasts.71–73 How-
ever, in gastric epithelial cells, we and others have found
weak22 74 or no expression11 21 75 76 of LMP1 in EBV associated
gastric cancers. Imai et al showed that in EBV associated gas-
tric cancers inactivation of LMP1, in addition to EBNA1,
EBNA2, EBNA3A, EBNA3B, EBNA3C, and Lp, was accom-
plished by the methylation of LMP1 regulatory sequences and
the C and W promoter regions.11
Sugiura et al have described the latency pattern of EBV in
gastric cancer as more closely resembling the latency I pattern
in Burkitt’s lymphoma, rather than the latency II pattern of
most nasopharyngeal carcinomas.75 That study reported the
finding in gastric cancers of transcripts for EBNA1 (initiated
from the Q promoter), LMP2A, and the BamHI-A regions of
the viral genome, but no transcripts of LMP1, LMP2B, or
EBNA2. Similarly, zur Hausen et al have described a transcrip-
tion pattern that includes BARF1, BARF0, LMP2A, and Q/K
driven EBNA1 but not LMP1, EBNA2, or ZEBRA transcripts in
EBV associated gastric cancers.76 Those authors described a
distinctive pattern of expression for gastric cancer that resem-
bles that of Burkitt’s lymphoma except for the additional
transcription of BARF1 and LMP2A in gastric cancer.
zur Hausen et al have proposed that BARF1 may substitute
for LMP1 in its oncogenic potential in gastric cancer.76 BARF1
can transform fibroblasts77 and immortalise kidney epithelial
cells in culture.78 The overexpression of BARF1 can activate the
c-myc proto-oncogene in Louckes B cells.79 BARF1 has a region
of homology to c-fms, a tyrosine kinase proto-oncogene,
which encodes the colony stimulating factor 1 receptor.80
BARF1 may help the virus to evade the immune system by
acting as an antagonist to colony stimulating factor 1, which is
a macrophage/monocyte growth and differentiation factor
(reviewed in Hamilton81).
“Neither of the promoters of the tumour suppressor genes
hMLH1 and hMSH2 appeared to be methylated in our
set of tumours”
It is possible that CDKN2A promoter methylation in EBV
associated gastric cancers is a cellular change secondary to the
acceleration of cell proliferation caused by the presence of a
viral oncogene such as BARF1. An alternative possibility is
that CDKN2A promoter methylation is more directly related to
the activities of the virus, and that the ability of the virus to
achieve methylation of its own genes for evasion of immune
surveillance may be accompanied by the ability to influence
the methylation of cellular tumour suppressor genes. If this
last hypothesis is true, it is noteworthy that there is apparently
some specificity of the cellular tumour suppressor genes that
become methylated because neither of the promoters of the
tumour suppressor genes hMLH1 and hMSH2 appeared to be
methylated in our set of tumours. This we infer from the fact
that no EBV positive cases were MSI-H, a defect that results
from inactivation of the DNA mismatch repair system, usually
caused, in gastric cancers, by hMLH1 or hMSH2 promoter
methylation.82 83 A leukaemia model demonstrates how an
oncogene can cause methylation of a promoter of a specific
Figure 2 (A) Immunohistochemical staining using an antibody
against p16 in this Epstein-Barr virus (EBV) associated gastric cancer
reveals that tumour cell nuclei (arrowhead) have no detectable p16
protein, in contrast to the p16 positive inflammatory and stromal cells
adjacent to the tumour (arrow) and to the p16 positive staining tumour
nuclei in the EBV negative carcinoma (B). Haematoxylin stained.
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tumour suppressor gene. In this model system, a leukaemia
promoting chimaeric oncogene, PML-RAR, is able to recruit
DNA methyltransferases to the promoter of the tumour
suppressor gene RARβ2, thus reducing its expression by
hypermethylation of the promoter.84 Whether the effect of EBV
upon CDKN2A promoter methylation is direct or indirect, the
increased proportion of promoter methylation detected in EBV
associated tumours compared with non-EBV associated
tumours is thought provoking. In summary, we have identified
a distinct pattern of epigenetic alteration in EBV associated
gastric cancers. Such distinctiveness might become relevant to
treatment in the event that treatments based on the reversal of
aberrant methylation become available.
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